Angiopoietins 1 and 2 in sputum supernatant of optimally treated asthmatics: The effect of smoking

European Journal of Clinical Investigation

Volumn 45, Issue 1, 2015, Pages 56-62

  Petta, Vasiliki ^a   Bakakos, Petros ^a   Tseliou, Eleni ^a   Kostikas, Konstantinos ^a   Simoes, Davina C M ^a   Konstantellou, Elissavet ^a   Hillas, Georgios ^b   Koulouris, Nikolaos G ^a   Papiris, Spyros ^a   Loukides, Stelios ^a  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^b SOTIRIA GENERAL HOSPITAL   (Greece)

Author keywords

Angiogenesis; Angiopoietins; Asthma; Inflammation; Smoking

Indexed keywords

ANGIOPOIETIN 1; ANGIOPOIETIN 2; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; EOSINOPHIL CATIONIC PROTEIN; GELATINASE A; INTERLEUKIN 13; INTERLEUKIN 8; LEUKOTRIENE RECEPTOR BLOCKING AGENT; TRANSFORMING GROWTH FACTOR BETA1; VASCULOTROPIN; ANTIASTHMATIC AGENT;

ADULT; AIRWAY VASCULAR PERMEABILITY INDEX; ANGIOGENESIS; ARTICLE; ASTHMA; BRONCHUS HYPERREACTIVITY; CONTROLLED STUDY; FEMALE; HUMAN; LUNG FUNCTION TEST; MAJOR CLINICAL STUDY; MALE; MEASUREMENT; PRIORITY JOURNAL; SMOKING; SPUTUM LEVEL; SUPERNATANT; UPREGULATION; ADVERSE EFFECTS; CASE CONTROL STUDY; CHEMISTRY; FORCED EXPIRATORY VOLUME; METABOLISM; MIDDLE AGED; NEOVASCULARIZATION (PATHOLOGY); PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY; SPUTUM; VITAL CAPACITY;

ADULT; ANGIOPOIETIN-1; ANGIOPOIETIN-2; ANTI-ASTHMATIC AGENTS; ASTHMA; CASE-CONTROL STUDIES; FORCED EXPIRATORY VOLUME; HUMANS; MALE; MATRIX METALLOPROTEINASE 2; MIDDLE AGED; NEOVASCULARIZATION, PATHOLOGIC; SMOKING; SPUTUM; VITAL CAPACITY;

EID: 84921047306     PISSN: 00142972     EISSN: 13652362     Source Type: Journal    
DOI: 10.1111/eci.12379     Document Type: Article

References (30)

1. Zanini A, Chetta A, Imperatori AS, Spanevello A, Olivieri D. The role of the bronchial microvasculature in the airway remodelling in asthma and COPD. Respir Res 2010;11:132.
2. Walters EH, Soltani A, Reid DW, Ward C. Vascular remodelling in asthma. Curr Opin Allergy Clin Immunol 2008;8:39-43.
3. Lee J, Cooke JP. Nicotine and pathological angiogenesis. Life Sci 2012;91:1058-64.
4. Papadaki G, Bakakos P, Kostikas K, Hillas G, Tsilogianni Z, Koulouris NG et al. Vascular endothelial growth factor and cysteinyl leukotrienes in sputum supernatant of patients with asthma. Respir Med 2013;107:1339-45.
5. Calabrese C, Bocchino V, Vatrella A, Marzo C, Guarino C, Mascitti S et al. Evidence of angiogenesis in bronchial biopsies of smokers with and without airway obstruction. Respir Med 2006;100:1415-22.
6. Thurston G, Rudge JS, Ioffe E, Zhou H, Ross L, Croll SD et al. Angiopoietin-1 protects the adult vasculature against plasma leakage. Nat Med 2000;6:460-3.
7. Kanazawa H. VEGF, angiopoietin-1 and -2 in bronchial asthma: new molecular targets in airway angiogenesis and microvascular remodeling. Recent Pat Inflamm Allergy Drug Discov 2007;1:1-8.
8. Kanazawa H, Nomura S, Asai K. Roles of angiopoietin-1 and angiopoietin-2 on airway microvascular permeability in asthmatic patients. Chest 2007;131:1035-41.
9. Tseliou E, Bakakos P, Kostikas K, Hillas G, Mantzouranis K, Emmanouil P et al. Increased levels of angiopoietins 1 and 2 in sputum supernatant in severe refractory asthma. Allergy 2012;67:396-402.
10. Kanazawa H, Asai K, Tochino Y, Kyoh S, Kodama T, Hirata K. Increased levels of angiopoietin-2 in induced sputum from smoking asthmatic patients. Clin Exp Allergy 2009;39:1330-7.
11. Bateman ED, Hurd SS, Barnes PJ, Bousquet J, Drazen JM, FitzGerald M et al. Global strategy for asthma management and prevention: GINA executive summary. Eur Respir J 2008;31:143-78.
12. Simera I, Moher D, Hoey J, Schulz KF, Altman DG. A catalogue of reporting guidelines for health research. Eur J Clin Invest 2010;40:35-53.
13. Kips JC, Fahy JV, Hargreave FE, Ind PW, in't Veen JC. Methods for sputum induction and analysis of induced sputum: a method for assessing airway inflammation in asthma. Eur Respir J Suppl 1998;26:9S-12S.
14. Grootendorst DC, van den Bos JW, Romeijn JJ, Veselic-Charvat M, Duiverman EJ, Vrijlandt EJ et al. Induced sputum in adolescents with severe stable asthma. Safety and the relationship of cell counts and eosinophil cationic protein to clinical severity. Eur Respir J 1999;13:647-53.
15. Efthimiadis A, Spanevello A, Hamid Q, Kelly MM, Linden M, Louis R et al. Methods of sputum processing for cell counts, immunocytochemistry and in situ hybridisation. Eur Respir J Suppl 2002;37:19s-23s.
16. Nathan RA, Sorkness CA, Kosinski M, Schatz M, Li JT, Marcus P et al. Development of the asthma control test: a survey for assessing asthma control. J Allergy Clin Immunol 2004;113:59-65.
17. Standardization of Spirometry. 1994 update. American Thoracic Society. Am J Respir Crit Care Med 1995;152:1107-36.
18. Kanazawa H, Nomura S, Yoshikawa J. Role of microvascular permeability on physiologic differences in asthma and eosinophilic bronchitis. Am J Respir Crit Care Med 2004;169:1125-30.
19. Rao SP, Sikora L, Hosseinkhani MR, Pinkerton KE, Sriramarao P. Exposure to environmental tobacco smoke induces angiogenesis and leukocyte trafficking in lung microvessels. Exp Lung Res 2009;35:119-35.
20. Ng MK, Wu J, Chang E, Wang BY, Katzenberg-Clark R, Ishii-Watabe A et al. A central role for nicotinic cholinergic regulation of growth factor-induced endothelial cell migration. Arterioscler Thromb Vasc Biol 2007;27:106-12.
21. Hoshino M, Takahashi M, Aoike N. Expression of vascular endothelial growth factor, basic fibroblast growth factor, and angiogenin immunoreactivity in asthmatic airways and its relationship to angiogenesis. J Allergy Clin Immunol 2001;107:295-301.
22. Delimpoura V, Bakakos P, Tseliou E, Bessa V, Hillas G, Simoes DC et al. Increased levels of osteopontin in sputum supernatant in severe refractory asthma. Thorax 2010;65:782-6.
23. Asai K, Kanazawa H, Kamoi H, Shiraishi S, Hirata K, Yoshikawa J. Increased levels of vascular endothelial growth factor in induced sputum in asthmatic patients. Clin Exp Allergy 2003;33:595-9.
24. Bae YJ, Kim TB, Moon KA, Lee KY, Park CS, Seo JB et al. Vascular endothelial growth factor levels in induced sputum and emphysematous changes in smoking asthmatic patients. Ann Allergy Asthma Immunol 2009;103:51-6.
25. Ribatti D, Puxeddu I, Crivellato E, Nico B, Vacca A, Levi-Schaffer F. Angiogenesis in asthma. Clin Exp Allergy 2009;39:1815-21.
26. Loffek S, Schilling O, Franzke CW. Series "matrix metalloproteinases in lung health and disease": biological role of matrix metalloproteinases: a critical balance. Eur Respir J 2011;38:191-208.
27. Chaudhuri R, McSharry C, Brady J, Donnelly I, Grierson C, McGuinness S et al. Sputum matrix metalloproteinase-12 in patients with chronic obstructive pulmonary disease and asthma: relationship to disease severity. J Allergy Clin Immunol 2012;129:655-63 e8.
28. Tomlinson JE, McMahon AD, Chaudhuri R, Thompson JM, Wood SF, Thomson NC. Efficacy of low and high dose inhaled corticosteroid in smokers versus non-smokers with mild asthma. Thorax 2005;60:282-7.
29. Clearie KL, McKinlay L, Williamson PA, Lipworth BJ. Fluticasone/Salmeterol combination confers benefits in people with asthma who smoke. Chest 2012;141:330-8.
30. Oikonomou KA, Kapsoritakis AN, Kapsoritaki AI, Manolakis AC, Tiaka EK, Tsiopoulos FD et al. Angiogenin, angiopoietin-1, angiopoietin-2, and endostatin serum levels in inflammatory bowel disease. Inflamm Bowel Dis 2011;17:963-70.